Eli Lilly Crushes Q1 Earnings and Raises 2026 Profit Forecast as Zepbound & Mounjaro Sales Explode
Eli Lilly raised profit outlook thanks to strong Zepbound & Mounjaro sales; revenue and earnings beat expectations, stock rose.
/ 1659 items
#XY↓
Teva Beats Q1 2026 Forecasts as AUSTEDO & UZEDY Surge — Acquires Emalex for $700M Tourette Drug
Teva buys Emalex for $700M to add a new Tourette drug. Strong sales growth led by key medicines; generics weaker but outlook solid.
Chiesi Buys KalVista for $1.9 Billion in Biggest Deal Yet to Strengthen Rare Disease Portfolio
Chiesi will buy KalVista for $1.9B to get EKTERLY, a new oral rare disease drug, and grow its global rare disease business.
Humana Beats Q1 2026 Earnings Expectations, Reaffirms Full-Year Adjusted Profit Guidance
Humana beat Q1 2026 expectations, revenue rose, Medicare membership grew, outlook steady but GAAP cut due to lower ratings.
Guggenheim Slaps Buy Rating on CRBP: $45 Target Signals Massive Upside
Corbus Pharmaceuticals gets Buy rating ($45 target). Drug CRB-701 shows strong cancer results, safer than rivals. Stock down 43% may be opportunity.
Guardant Health Shares Fall After FDA Raises Concerns on AstraZeneca Breast Cancer Drug
Guardant stock fell after FDA raised doubts on a key drug study. Delay fears hurt short-term, but long-term outlook still strong.